Thus, inhibiting the interaction between LPS and TLR4, or obstructing the subsequent signaling cascade, can limit macrophage activation and the production of inflammatory mediators, hence enhancing the immune system ability to identify and target cancer cells, which improves anti-tumor immune responses [72,73]. The gene discussed is TLR4; the disease is cancer.